Signature Based on Six Autophagy-related Genes to Predict Prognosis of Head and Neck Squamous Cell Carcinoma

Abstract

Objective

The present study aimed to develop an autophagy-related gene prognostic prediction model to provide survival risk prediction for head and neck squamous cell carcinoma (HNSCC) patients.

Methods

The K-mean cluster analysis was performed on HNSCC samples based on the expression values of 210 autophagy-related genes for candidate signature gene selection. LASSO Cox regression analysis was generated using the potential genes and the risk score was calculated from the prognosis model. The risk score was processed as an independent prognostic indicator to construct the nomogram model. The immune status including immune cell infiltration ratio and checkpoints of patients with HNSCC in high- and low-risk groups was also explored.

Results

LASSO Cox regression analysis was performed on the selected autophagy-related genes. According to the lambda value corresponding to the number of different genes in the LASSO Cox analysis, six genes (GABARAPL2, SAR1A, ST13, GAPDH, FADD and LAMP1) were finally chosen. The risk score based on the genes was generated, which was an independent prognostic marker for HNSCC. The prognostic prediction model (nomogram) was further optimized by the independent prognostic factors (risk score), which can better predict the prognosis and survival of patients. With the risk score and prognosis model, eight types of immune cells and six key immune checkpoints (CTLA4, PD1, IDO1, TDO2, LAG3, TIGIT) displayed expression specificity.

Conclusion

This study identified several potential prognostic biomarkers and established an autophagy-related prognostic prediction model for HNSCC, which provides a valuable reference for future clinical research.

Keywords

head and neck squamous cell carcinoma / autophagy / risk score / Cox regression / nomogram / immune cell infiltration ratio

References

[1] JouA, HessJ. Epidemiology and Molecular Biology of Head and Neck Cancer. Oncol Res Treat, 2017, 40(6): 328-332

[2] CramerJD, BurtnessB, LeQT, et al.. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol, 2019, 16(11): 669-683

[3] KawakitaD, MatsuoK. Alcohol and head and neck cancer. Cancer Metastasis Rev, 2017, 36(3): 425-434

[4] MarurS, ForastiereAA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc, 2016, 91(3): 386-396

[5] PrzybylskiK, MajchrzakE, WeselikL, et al.. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade. Otolaryngol Pol, 2018, 72(6): 10-16

[6] OlivaM, SpreaficoA, TabernaM, et al.. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol, 2019, 30(1): 57-67

[7] HuangSH, O’SullivanB. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol, 2017, 18(7): 40

[8] Saada-BouzidE, PeyradeF, GuigayJ. Molecular genetics of head and neck squamous cell carcinoma. Curr Opin Oncol, 2019, 31(3): 131-137

[9] GalluzziL, GreenDR. Autophagy-Independent Functions of the Autophagy Machinery. Cell, 2019, 177(7): 1682-1699

[10] AmaravadiR, KimmelmanAC, WhiteE. Recent insights into the function of autophagy in cancer. Genes Dev, 2016, 30(17): 1913-1930

[11] CoswayB, LovatP. The role of autophagy in squamous cell carcinoma of the head and neck. Oral oncol, 2016, 54: 1-6

[12] AntunesF, ErustesAG, CostaAJ, et al.. Autophagy and intermittent fasting: the connection for cancer therapy?. Clinics, 2018, 73(suppl1): e814s

[13] LiYJ, LeiYH, YaoN, et al.. Autophagy and multidrug resistance in cancer. Chin J Cancer, 2017, 36(1): 52

[14] LevyJMM, TowersCG, ThorburnA. Targeting autophagy in cancer. Nat Rev Cancer, 2017, 17(9): 528-542

[15] FriedmanJ, HastieT, TibshiraniR. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw, 2010, 33(1): 1-22

[16] HeagertyPJ, LumleyT, PepeMS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics, 2000, 56: 337-344

[17] NewmanAM, LiuCL, GreenMR, et al.. Robust enumeration of cell subsets from tissue expression profiles. Nat methods, 2015, 12(5): 453-457

[18] SolomonB, YoungRJ, RischinD. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol, 2018, 52: 228-240 Pt 2

[19] ShibutaniST, SaitohT, NowagH, et al.. Autophagy and autophagy-related proteins in the immune system. Nat Immunol, 2015, 16(10): 1014-1024

[20] GrandisJR, FalknerDM, MelhemMF, et al.. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res, 2000, 6(7): 2794-2802

[21] MizukamiY, KonoK, MaruyamaT, et al.. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer, 2008, 99(9): 1462-1467

[22] StraussL, BergmannC, GoodingW, et al.. The frequency and suppressor function of CD4+CD25 high Foxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res, 2007, 13(21): 6301-6311

[23] ZouW, ChenL. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol, 2008, 8(6): 467-477

[24] SchaafMB, KeulersTG, VooijsMA, et al.. LC3/GABARAP family proteins: autophagy-(un)related functions. FASEB J, 2016, 30: 3961-3978

[25] ButeraG, MullappillyN, MasettoF, et al.. Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in Cancer and Neurodegenerative Disorders. Int J Mol Sci, 2019, 20(9): 2062

[26] AntunovicM, MaticI, NagyB, et al.. FADD-deficient mouse embryonic fibroblasts undergo RIPK1-dependent apoptosis and autophagy after NB-UVB irradiation. J Photochem Photobiol B, 2019, 194: 32-45

[27] ChengXT, XieYX, ZhouB, et al.. Revisiting LAMP1 as a marker for degradative autophagy-lysosomal organelles in the nervous system. Autophagy, 2018, 14(8): 1472-1474

[28] LiuG, ZhengJ, ZhuangL, et al.. A Prognostic 5-lncRNA Expression Signature for Head and Neck Squamous Cell Carcinoma. Sci Rep, 2018, 8(1): 15250

[29] CheongJE, SunL. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy — Challenges and Opportunities. Trends Pharmacol Sci, 2018, 39(3): 307-325

[30] HattoriS, TakaoK, FunakoshiH, et al.. Comprehensive behavioral analysis of tryptophan 2,3-dioxygenase (Tdo2) knockout mice. Neuropsychopharmacol Rep, 2018, 38(2): 52-60

[31] PhamQT, OueN, SekinoY, et al.. TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma. Oncology, 2018, 95(5): 297-308